Summary
The past decade of efforts to find improved treatment for major depression has been dominated by genome-driven programs of rational drug discovery directed toward highly selective ligands for nonmonoaminergic agents. Selective drugs may prove beneficial for specific symptoms, for certain patient subpopulations, or both. However, network analyses of the brain and its dysfunction suggest that agents with multiple and complementary modes of action are more likely to show broad-based efficacy against core and comorbid symptoms of depression. Strategies for improved multitarget exploitation of monoaminergic mechanisms include triple inhibitors of dopamine, serotonin (5-HT) and noradrenaline reuptake, and drugs interfering with feedback actions of monoamines at inhibitory 5-HT1A, 5-HT1B and possibly 5-HT5A and 5-HT7 receptors. Specific subsets of postsynaptic 5-HT receptors mediating antidepressant actions are under study (e.g., 5-HT4 and 5-HT6). Association of a clinically characterized antidepressant mechanism with a nonmonoaminergic component of activity is an attractive strategy. For example, agomelatine (a melatonin agonist/5-HT2C antagonist) has clinically proven activity in major depression. Dual neurokinin1 antagonists/5-HT reuptake inhibitors (SRIs) and melanocortin4 antagonists/SRIs should display advantages over their selective counterparts, and histamine H3 antagonists/SRIs, GABAB antagonists/SRIs, glutamatergic/SRIs, and cholinergic agents/SRIs may counter the compromised cognitive function of depression. Finally, drugs that suppress 5-HT reuptake and blunt hypothalamo-pituitary-adrenocorticotrophic axis overdrive, or that act at intracellular proteins such as GSK-3β, may abrogate the negative effects of chronic stress on mood and neuronal integrity. This review discusses the discovery and development of dual- and triple-acting antidepressants, focusing on novel concepts and new drugs disclosed over the last 2 to 3 years.
Article PDF
Similar content being viewed by others
References
Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29:1765–1781.
Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2007;7:193–218.
Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110, 135–370.
Millan MJ. The discovery and development of pharmacotherapy for psychiatric disorders: a critical survey of animal and translational models, and perspectives for their improvement. In: McArthur R, Borsini F, Translational models for CNS drug discovery. Vol 1: Psychiatric disorders. New York: Academic Press, 2008;32–89.
Hollon SD, Stewart MO, Strunk D. Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annu Rev Psychol 2006;57:285–315.
Eitan R, Lerer B. Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin Neurosci 2006;8:241–258.
Baghai TC, Grunze H, Sartorius N. Antidepressant medications and other treatments of depressive disorders: a CINP task force report based on a review of evidence. Int J Neuropsychopharmacol 2007;10 Suppl 1:S1-S207.
O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208–1216.
Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137–151.
Castrén E. Is mood chemistry? Nat Rev Neurosci 2005;6:241–246.
Csermely P. Strong links are important, but weak links stabilize them. Trends Biochem Sci 2004;29:331–334.
Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:180–182.
Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem 2006;49: 4961–4970.
Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov Today 2007;12:156–160.
Wong EHF, Nikam SS, Shahid M. Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 2008;9:28–36.
Huang S. Rational drug discovery: what can we learn from regulatory networks? Drug Discov Today 2002;7(20 Suppl): S163-S169.
Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 2008;9: 638–646.
Cooper-Kazaz, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008;11:685–699.
McIntyre M, Moral MA. Augmentation in treatment-resistant depression. Drugs Fut 2006;31:1069–1081.
Rasmussen K. Creating more effective antidepressants: clues from the clinic. Drug Discov Today 2006;11:623–631.
Rojo JE, Ros S, Agitera L, de la Gándara J, de Pedro JM. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl 2005;(428):25–31.
Ros S, Agüera L, de la Gándara J, Rojo JE, de Pedro JM. Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand Suppl 2005;(428):14–24,36.
Benedetti F, Barbini B, Colombo C, Smeraldi E. Chronotherapeutics in a psychiatric ward. Sleep Med Rev 2007;11:509–522.
Barrett J, Della-Maggiore V, Chouinard PA, Paus T. Mechanisms of action underlying the effect of repetitive transcranial magnetic stimulation on mood: behavioral and brain imaging studies. Neuropsychopharmacology 2004;29: 1172–1189.
Kraus T, Hösl K, Kiess O, et al. BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect of transcutaneous vagus nerve stimulation. J Neural Transm 2007;114:1485–1493.
Johansen-Berg H, Gutman DA, Behrens TEJ, et al. Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cereb Cortex 2007;18:1374–1383.
Roffman JL, Marci CD, Glick DM, Dougherty DD, Rauch SL. Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol Med 2005;35:1385–1398.
De Maat SM, Dekker J, Schoevers RA, de Jonghe F. Relative efficacy of psychotherapy and combined therapy in treatment of depression: a meta-analysis. Eur Psychiatry 2007;22:1–8.
Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 2007;164:778–788.
Luty SE, Carter JD, McKenzic JM, et al. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioral therapy for depression. Br J Psychiatry 2007;190:496–502.
Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affective Dis 2000;58:19–36.
Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Design 2004;10:2463–2475.
Tegeder I, Geisslinger G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol 2006;373:1–17.
Millan MJ, Brocco M. Cognitive impairment in schizophrenia: developmental and genetic models, and pro-cognitive profile of the optimised D3>D2 antagonist, S33138. Therapic 2008;63:187–229.
Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178:129–144.
Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand 2005;111:94–105.
Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217–1227.
Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323–329.
Devoto P, Flore G, Pira L, Longu G, Gessa GL. Mirtazapine-induced co-release of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol 2004;487: 105–111.
Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 2000;14:114–138.
Nestler EJ, Carlzon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59: 1151–1159.
Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: influences on male sexual behavior. Physiol Behav 2004;83:291–307.
El-Ghundi M, O’Dowd BF, George SR. Insights into the role of dopamine receptor systems in learning and memory. Rev Neurosci 2007;18:37–66.
Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243–1252.
Rica C, Hascoet M, Bourin M. Is co-administration of bupropion with SSRIs and SNRIs in forced swim test in mice predictive of efficacy in resistant depression? Behav Brain Res 2008;194:92–99.
Axford L, Boot JR, Hotten TM, et al. Bicyclo[2.2.1.]heptanes as novel triple re-uptake inhibitors for the treatment of depression. Bioorg Med Chem Lett 2003;13:3277–3280.
Shaw AM, Boules M, Zhang Y, et al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol 2007;555:30–36.
Skolnick P, Basile AS. Triple reuptake inhibitors as antidepressants. Drug Discov Today Ther Strateg 2006;3:489–494.
Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a “triple” reuptake inhibitor. CNS Drug Rev 2006;12:123–134.
Zhang S, Fernandez F, Hazeldine S, et al. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters. J Med Chem 2006;49:4239–4247.
Aluisio L, Lord B, Barbier AJ, et al. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur J Pharmacol 2008;587:141–146.
Samaha AN, Robinson TE. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 2005;26:82–87.
Volkow ND, Wang GJ, Fowler JS, et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry 2005;57:640–646.
Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease. Mov Disord 2007;22:359–365.
Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006;7:139–147.
Gobert A, Millan MJ. Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (−)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of β-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology 1999;21:268–284.
Bymaster FP, McNamara RK, Tran PV. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin Investig Drugs 2003;12:531–543.
Celada P, Puig MV, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252–265.
Weikop P, Kehr J, Scheel-Krüger J. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine in the rat prefrontal cortex: the role of 5-HT1A receptors. J Psychopharmacol 2007;21:795–804.
Dawson LA, Bromidge SM. 5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders. Curr Top Med Chem 2008;8:1008–1023.
Rex A, Voigt JP, Wicke KM, Fink H. In vivo/ex vivo and behavioural study on effects of 5-HT1B/1D and 5-HT1A antagonists in guinea pigs. Pharmacol Biochem Behav 2008;88:196–204.
Hatzenbuhler NT, Evrard DA, Harrison BL, et al. Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with 5-HT1A receptor and serotonin transporter affinity. J Med Chem 2006;49: 4785–4789.
Butler SG, Meegan J. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter. Curr Med Chem 2008;15:1737–1761.
Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of α2-adrenergic receptors underlic its actions. Neuroscience 1999;93:1251–1262.
De Paulis T. Drug evaluation: vilazodone—a combined SSRI and 5-HT1A partial agonist for the treatment of depression. Idrugs 2007;10:193–201.
Jordan S, Chen R, Koprivica V, et al. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors. Eur J Pharmacol 2005;517:165–173.
Tottori K, Miwa T, Uwahodo Y, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001;41:976–988.
Millan MJ, Marin P, Bockaert J, Mannoury 1a Cour C. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 2008;29:454–64.
Heightman TD, Gaster LM, Pardoe SL, et al. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bio-available 5-HT1 receptor ligands. Bioorg Med Chem Lett 2005;15:4370–4374.
Ward SE, Eddershaw PJ, Scott CM, et al. Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists. J Med Chem 2008;51:2887–2890.
Hughes ZA, Starr KR, Scott CM, et al. Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacology (Berl) 2007;192:121–133.
Starr KR, Price GW, Watson JM, et al. SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat social interaction test. Neuropsychopharmacology 2007;32:2163–2172.
Watson JM, Dawson LA. Characterization of the potent 5-HT1A/B receptor antagonist and serotonin reuptake inhibitor SB-649915: preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy. CNS Drug Rev 2007;13:206–223.
Millan MJ, Gobert A, Roux S, et al. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. J Pharmacol Exp Ther 2004;311:190–203.
King MV, Marsden CA, Fone KCF. A role of the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci 2008;29:482–492.
Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E. Effect of the selective 5-HT7 receptor antagonist SB269,970 in models of anxiety and depression. Neuropharmacology 2006;51:578–586.
Wesołowska A, Tatarczyńska E, Nikiforuk A, Chojnacka-Wôjcik E. Enhancement of the anti-immobility action of antidepressant by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur J Pharmacol 2007;555:43–47.
Bonaventure P, Kelly L, Aluisio L, et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 2007;321:690–698.
Mnie-Filali O, Lambas-Senas L, Zimmer L, Haddjeri N. 5-HT7 receptor antagonists as a new class of antidepressants. Drug News Perspect 2007;20:613–618.
Thomas DR, Melotto S, Massagrand M, et al. SB656,104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol 2003;139:705–714.
McClung CA. Orcadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007;114:222–232.
Bunney JN, Potkin SG. Orcadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull 2008;86:23–32.
Thomas DR. 5-HT5A receptors as a therapeutic target. Pharmacol Ther 2006;111:707–714.
Thomas DR, Soffin EM, Roberts C, et al. SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4′-([(2-phenylethyl) amino]methyl)-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain. Neuropharmacology 2006;51:566–577.
Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapic 2005;60:441–460.
Dekeyne A, Mannoury la Cour C, Gobert A, et al. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) 2008;199:549–568.
Cremers TI, Rea K, Bosker FJ, et al. Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. Neuropsychopharmacology 2007;32:1550–1557.
Heisler LK, Pronchuk N, Nonogaki K, et al. Serotonin activates the hypothalamic-pituitary-adrenal axis via 5-HT2C receptor stimulation. J Neurosci 2007;27:6956–6964.
Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH. Serotonin 5-HT2C receptors regulate anxiety-like behavior. Genes Brain Behav 2007;6:491–496.
Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83–244.
Kantor S, Jakus R, Molnar E, et al. Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power spectra. J Pharmacol Exp Ther 2005;315:921–930.
Dekeyne A, Denorme B, Monneyron S, Millan MJ. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)2C receptors. Neuropharmacology 2000;39:1114–1117.
Salchner P, Singewald N. 5-HT receptor subtypes involved in anxiogenic-like action and Fos response of acute fluoxetine treatment in rats. Psychopharmacology (Berl) 2006;185:282–288.
Dekeyne A, Mannoury la Cour C, Chanrion B, et al. S32212, a “dual” antagonist at α2-adrenoceptors (ARs) and 5-HT2C receptors: binding profile and functional action at G-protein-coupled receptors. Am Soc Neurosci Abstr 2006;32:828.2 (abstract).
Gobert A, Dekeyne A, Brocco M, et al. S32212, a “dual” antagonist at α2-adrenoceptors (ARs) and 5-HT2C receptors: actions in behavioral and neurochemical models of potential antidepressant and pro-cognitive activity. Am Soc Neurosci Abstr 2006;32:828.3 (abstract).
Rauggi R, Cassanelli A, Raone A, Tagliamonte A, Gambarana C. Study of mirtazapine antidepressant effects in rats. Int J Neuropsychopharmacol 2005;8:369–379.
Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 2005;6:631–641.
Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and adrenergic, but not serotonergic, transmission by blockade of α2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 2000;12:1079–1095.
Tam SW, Worcel M, Wyllic M. Yohimbine: a clinical review. Pharmacol Ther 2001;91:215–243.
Invemizzi RW, Garattini S. Role of presynaptic α2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:819–827.
Lapiz MD, Morilak DA. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 2006;137:1039–1049.
Hemrick-Luecke SK, Evans DC. Comparison of the potency of MDL100,907 and SB242,084 in blocking 5-HT2 agonist-induced increases corticosterone: evidence for 5-HT2A mediation of HPA axis. Neuropharmacology 2002;42:162–169.
Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008;29:445–453.
Fujiwara-Sawada M, Imanishi T, Yoshida A, Baba J. Possible involvement of peripheral 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus. J Pharm Pharmacol 2003;55:271–274.
Costall B, Naylor RJ. 5-HT3 receptors. Curr Drug Targets 2004;3:27–37.
Harmer CJ, Reid CB, Ray MK, Goodwin GM, Cowen PJ. 5-HT3 antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology (Berl) 2006;186:18–24.
Ramamoorthy R, Radhakrishnan M, Borah M. Antidepressant-like effects of 5-HT3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav Pharmacol 2008;19:29–40.
Moore NA, Bang-Andersen B, Brennum LT, et al. Lu AA21004: a novel potential treatment for mood disorders. Eur Neuropsychopharmacol 2008;18 Suppl 4:S321 (abstract).
Millan MJ, Di Cara B, Dekeyne A, et al. Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neuro-chemical and behavioural analysis. J Neurochem 2007;100:1047–1061.
Loiseau F, Millan MJ. Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D1 receptor agonists, but not of D2 antagonists. Eur Neuropsychopharmacol 2008 Sept 14 [Epub ahead of print].
Norman TR, Burrows GD. Emerging treatments for major depression. Expert Rev Neurother 2007;7: 203–213.
Stone EA, Quartermain D, Lin Y, Lehmann ML. Central α1-adrenergic system in behavioral activity and depression. Biochem Pharmacol 2007;73:1063–1075.
Zhang HT, Huang Y, Mishler K, Roerig SC, O’Donnell JM. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats. Psychopharmacology (Berl) 2005;182:104–115.
Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective β3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacol Biochem Behav 2008;89:623–626.
Stemmelin J, Cohen C, Terranova JP, et al. Stimulation of the β3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008;89:574–587.
Maurel JL, Autin JM, Funes O, Newman-Tancredi A, Colpaert F, Vacher B. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. J Med Chem 2007;50:5024–5033.
Lucas G, Rymar VV, Du J, et al. Serotonin4 (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007;55:712–725.
Svenningsson P, Tzavara ET, Qi H, et al. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci 2007;27:4201–4209.
Wesolowska A, Nikiforuk A. The selective 5-HT6 receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats. Eur J Pharmacol 2008;582:88–93.
Giaroni C, Canciani L, Zanetti E, et al. Effects of chronic desipramine treatment on α2-adrenoceptors and μ-opioid receptors in the guinea pig cortex and hippocampus. Eur J Pharmacol 2008;579:116–125.
Lapiz MD, Zhao Z, Bondi CO, O’Donnell JM, Morilak DA. Blockade of autoreceptor-mediated inhibition of norepinephrine release by atipamezole is maintained after chronic reuptake inhibition. Int J Neuropsychopharmacol 2007;10:827–833.
Sanacora G, Berman RM, Cappiello A, et al. Addition of the α2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology 2004;29:1166–1171.
Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of α2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetyl-cholinesterase inhibitors. J Pharmacol Exp Ther 2003;305:338–346.
Cordi AA, Berque-Bestel I, Persigand T, et al. Potential antidepressants display combined α2-adrenoceptor antagonist and monoamine uptake inhibitor properties. J Med Chem 2001;44:787–805.
Andrés JI, Alcazar J, Alonso JM, et al. Tricyclic isoxazolines: identification of R226161 as a new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism. Bioorg Med Chem 2007;15: 3649–3660.
Gobert A, Cussac D, Lejeune F, et al. The novel antidepressant, S35966, is a mixed serotonin and noradrenaline reuptake inhibitor and an antagonist at α2-adrenoceptors. Eur Neuropsychopharmacol 2002;12 Suppl 3:S248 (abstract).
Pérez-García C, Morales L, Cano MV, Sancho I, Alguacil LF. Effects of histamine H3 receptor ligands in experimental models of anxiety and depression. Psychopharmacology (Berl) 1999;142:215–220.
Passani MB, Lin JS, Hancock A, Crochet S, Blandina P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004;25:618–625.
Medhurst AD, Atkins AR, Beresford IJ, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321:1032–1045.
Keith JM, Gomez LA, Barbier AJ, et al. Pyrrolidino-tetrahydroisoquinolines bearing pendant heterocycles as potent dual H3 antagonist and serotonin transporter inhibitors. Bioorg Med Chem Lett 2007;17:4374–4377.
Barbier AJ, Aluisio L, Lord B, et al. Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor. Eur J Pharmacol 2007;576:43–54.
Hancock AA, Brune ME. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin Invest Drugs 2005;14:223–241.
Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol 2002;88:133–138.
Rabenstein RL, Caldarone BJ, Picciotto MR. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) 2006;189:395–401.
Mineur YS, Somenzi O, Picciotto MR. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 2007;52:1256–1262.
Andreasen JT, Olsen GM, Wiborg O, Redrobe JP. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacology 2008 June 26 [Epub ahead of print].
George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol 2008;28:340–344.
Abe Y, Aoyagi A, Hara T, et al. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer’s disease. J Pharmacol Sci 2003;93:95–105.
Toda N, Tago K, Marumoto S, et al. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer’s disease. Bioorg Med Chem 2003;11: 4389–4415.
Decker M. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini Rev Med Chem 2007;7:221–229.
Froestl W, Gallagher M, Jenkins H, et al. SGS742: the first GABAB receptor antagonist in clinical trials. Biochem Pharmacol 2004;68:1479–1487.
Slattery DA, Cryan JF. The role of GABAB receptors in depression and antidepressant-related behavioural responses. Drug Dev Res 2006;67:477–494.
Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depress Anxiety 2007;24:495–517.
Mannoury la Cour C, Hanoun N, Melfort M, et al. GABAB receptors in 5-HT transporter- and 5-HT1A knock-out mice: evidence of a transduction pathway shared with 5-HT1A receptors. J Neurochem 2004;89:886–896.
Cornelisse LN, Van der Harst JE, Lodder JC, et al. Reduced 5-HT1A and GABAB receptor function in dorsal raphe neurons upon chronic fluoxetine treatment of socially stressed rats. J Neurophysiol 2007;98:196–204.
Millan MJ. N-methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 2005;179:30–53.
Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 2003;1003:292–308.
Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits: a review of preclinical data. Psychopharmacology (Berl) 2005;179:154–163.
Linden AL, Schoepp DD. Metabotropic glutamate receptor targets for neuropsychiatric disorders. Drug Discov Today Ther Strateg 2006;3:507–517.
De Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005;6:463–475.
Umegaki H, Yamamoto A, Suzuki Y, Iguchi A. Stimulation of the hippocampal glutamate receptor systems induces stress-like responses. Neuro Endocrinol Lett 2006;27:339–343.
Ziegler DR, Cullinan WE, Herman JP. Organization and regulation of paraventricular nucleus glutamate signalling systems: N- methyl-d-aspartate receptors. J Comp Neurol 2005;484:43–56.
Rogoz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002;42:1024–1030.
Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856–864.
Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349–352.
Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system: too little activation is bad, too much is even worse. Neuropharmacology 2007;53: 699–723.
Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2003;2:503–505.
Karivajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:782–792.
Almeida RC, Felisbino CS, López MG, Rodrigues AL, Gabilan NH. Evidence for the involvement of l-arginine-nitric oxidecyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav Brain Res 2006;168:318–322.
Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in depression. Am J Psychiatry 2006;163:153–155.
Muhonen LH, Lonnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008;69:392–399.
Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 2003;44:1013–1021.
Li X, Witkin JM, Need AB, Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003;23:419–430.
Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets 2007;8:583–602.
Moriya T, Ikeda M, Teshima K, et al. Facilitation of α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor transmission in the suprachiasmatic nucleus by aniracetam enhances photic responses of the biological clock in rodents. J Neurochem 2003;85:978–987.
Gould TD, O’Donnell KC, Dow ER, Du J, Chen G, Manji HK. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 2008;54:577–587.
Korte SM. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev 2001;25: 117–142.
Matrisciano F, Panaccione I, Zusso M, et al. Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication? Mol Psychiatry 2007;12:704–706.
Brocco M, Dekeyne A, Mannoury la Cour C, et al. Cellular and behavioural profile of the novel, selective neurokinin, receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 2008;18:729–750.
Czéh B, Fuchs E, Simon M. NK, receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Investig Drugs 2006;15, 479–486.
Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385–392.
Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance P (neurokinin, receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216–223.
Millan MJ, Lejeune F, De Nanteuil G, Gobert A. Selective blockade of NK, receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 2001;76: 1949–1954.
Lejeune F, Gobert A, Millan MJ. The selective NK, antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study. Brain Res 2002;935:134–139.
Gobbi G, Cassano T, Radja F, et al. Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol 2007;17:328–338.
Guiard BP, Guilloux JP, Reperant C, Hunt SP, Toth M, Gardier AM. Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol 2007;72:1411–1418.
Gobert A, Brocco M, Dekeyne A, et al. Neurokinin, antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electro-physiological, and behavioral characterization. Neuropsychopharmacology 2008 Oct. 1 [Epub ahead of print].
Chenu F, Guiard BP, Bourin M, Gardier AM. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK, receptor antagonist in the mouse forced swimming test. Behav Brain Res 2006;172:256–263.
Millan MJ, Girardon S, Mullot J, Brocco M, Dekeyne A. Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists. Neuropharmacology 2002;42: 677–684.
Gannon RL, Millan MJ. The selective tachykinin neurokinin 1 (NK1) receptor antagonist, GR205,171, stereospecifically inhibits light-induced phase advances of hamster circadian activity rhythms. Eur J Pharmacol 2005;527:86–93.
Gannon RL, Millan MJ. Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms. Psychopharmacology (Berl) 2007;195:325–332.
Patel L, Lindley C. Aprepitant: a novel NKl-receptor antagonist. Expert Opin Pharmacother 2003;4: 2279–2296.
Ryckmans T, Balançon L, Berton O, et al. First dual NK, antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. Bioorg Med Chem Lett 2002;12:261–264.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent models. Pharmacol Biochem Behav 2008;89:36–45.
Micale V, Tamburella A, Leggio GM, Mazzola C, Li VV, Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol Biochem Behav 2008;90:463–469.
Serradeil-Le Gal C, Wagnon J 3rd, Tonnerre B, et al. An overview of SSR149415, a selective nonpeptide vasopressin V1b receptor antagonist for the treatment of stress related disorders. CNS Drug Rev 2005;11:53–68.
Landgraf R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol Disord Drug Targets 2006;5:167–188.
Hodgson RA, Higgins GA, Guthrie DH, et al. Comparison of the Vlb antagonist, SSR149415, and the CRF1 antagonist, CP154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 2007;86:431–440.
Ogren SO, Kuteeva E, Hokfelt T, Kehr J. Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs 2006;20:633–654.
Millan MJ, Gobert A, Panayi F, et al. The melanin-concentrating hormone] receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Int J Neuropsychopharmacol 2008;11:1105–1122.
Kehne JH. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007;6:163–182.
Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008;165:617–620.
Xi N. The MC4 receptor as a drug discovery target. Drugs Fut 2006;31:163–173.
Chaki S, Oshida Y, Ogawa S, et al. MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol Biochem Behav 2005;82:621–626.
Delia Zuana O, Sadlo M, Germain M, Félétou M, Chamorro S, Tisserand F. Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade. Int J Obes Relat Metab Disord 2001;25:84–94.
Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002;7:254–275.
DeBattista C, Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol Metab 2006;17:117–121.
Schick M, Kiefer F, Kämpf P, Arlt J, Wiedemann K, Jahn H. Cell-tumover in the gyrus dentatus in mice is enhanced by metyrapone treatment. Pharmacopsychiatry 2001;34:198.
Rogoz Z, Skuza G, Wojcikowski J, Daniel WA. Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol 2003;55:993–999.
Rogóz Z, Skuza G, Wojcikowski J, et al. Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol 2004;56:849–855.
Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedermann K. Metyrapone as additive treatment in major depression. Arch Gen Psychiatry 2004;61:1235–1244.
Gallagher P, Malik N, Newham J, Young AH, Ferner IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev 2008;(1):CD005168.
Oomen CA, Mayer JL, de Kloet ER, Joëls M, Lucassen PJ. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalizes the reduction in neurogenesis after chronic stress. Eur J Neurosci 2007;26:3395–3401.
Wu LM, Han H, Wang QN, et al. Mifepristone repairs region-dependent alteration of synapsin I in hippocampus in rat model of depression. Neuropsychopharmacology 2007;32:2500–2510.
Ago Y, Arikawa S, Yata M, et al. Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression. Neuropharmacology 2008 Aug. 30 [Epub ahead of print].
Schatzberg AF, Lindley S. Glucocorticoid antagonists in neuropsychiatric disorders. Eur J Pharmacol 2008;583:358–364.
Clark JA, Pai LY, Flick RB, Rohrer SP. Differential hormonal regulation of tryptophan hydroxylase-2 mRNA in the murine dorsal raphe nucleus. Biol Psychiatry 2005;57:943–946.
Johnson DA, Grant EJ, Ingram CD, Gartside SE. Glucocorticoid receptor antagonists hasten and augment neurochemical responses to a selective serotonin reuptake inhibitor antidepressant. Biol Psychiatry 2007;62:1228–1235.
Zupancic M, Guilleminault C. Agomelatine. CNS Drugs 2006;20:981–992.
Ghosh A, Hellewell JSE. A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin Investig Drugs 2007;16:1999–2004.
Lam RW. Addressing circadian rhythm disturbances in depressed patients. J Psychopharmacology 2008;22:13–18.
Srinivasan V, Smits M, Spence W, et al. Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138–151.
Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372–380.
Weil ZM, Hotchkiss AK, Gatien ML, Pieke-Dahl S, Nelson RJ. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull 2006;68:425–429.
Millan MJ, Brocco, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role or 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005;177:448–458.
Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-HT2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954–964.
Banasr M, Sounder A, Hery M, Mocaër E, Daszuta A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006;59:1087–1096.
Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93–100.
Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329–333.
Chenu F, Bourin M. Potentiation of antidepressant-like activity with lithium: mechanism involved. Curr Drug Targets 2006;7:159–163.
Crossley NA, Bauer M. Acceleration and augmentation of anti-depressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007;68:935–940.
Carbonell L, Cuffi ML, Forn J. Effect of chronic lithium treatment on the turnover of α2-adrenoceptors after chemical inactivation in rats. Eur Neuropsychopharmacol 2004;14:497–502.
Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005;30:1223–1237.
Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK-3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006;7:1421–1434.
Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 2007;31:920–931.
Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kmase-3β (GSK-3β) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004;29: 1426–1431.
Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol 2003;55:1143–1147.
Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus. Biol Psychiatry 2004;55:781–784.
Rosa AO, Kaster MP, Binfaré RW, et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1549–1556.
Ghavami A, Hirst WD, Novak TJ. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit? Drugs R D 2006;7:63–71.
Zhang HT, Huang Y, Masood A, et al. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 2008;33:1611–1623.
Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O’Donnell JM. Inhibition of PDE-4 reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CAI subregion of the rat hippocampus. Neuropsychopharmacology 2004;29:1432–1439.
Millan MJ. The role of monoamines in the actions of established and “novel” antidepressant agents: a critical review. Eur J Pharmacol 2004;500:371–384.
Chanrion B, Mannoury la Cour C, Bertaso F, et al. Physical interaction between serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of activity. Proc Natl Acad Sci U S A 2007;104:8119–8124.
Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007;131:596–610.
Martina M, Turcotte MEB, Halman S, Bergeron R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol 2007;578. 1;143–157.
Wang J, Mack AL, Coop A, Matsumoto RR. Novel sigma (σ) receptor agonists produce antidepressant-like effects in mice. Eur Neuropsychopharmacol 2007;17:708–716.
Paolini GV, Shapland RHB, van Hoom WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006;24:805–815.
Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008;321:263–266.
Hellerstein MK. Exploiting complexity and the robustness of network architecture for drug discovery. J Pharmacol Exp Ther 2008;325:1–9.
Evrard DA. Recent strategies for the development of new antidepressant drugs. Annu Rep Med Chem 2006;41:24–37.
Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Structural Biol 2006;16:127–136.
Yeh P, Tschumi AI, Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat Genet 2006;38:489–494.
Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drugtarget network. Nat Biotechnol 2007;25:1119–1126.
Keiser MJ, Roth BL, Armbruster BN, Emsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25:197–206.
Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R. Novel paradigms for drug discovery: computational multi-target screening. Trends Pharmacol Sci 2008;29:62–71.
Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007;13:5232–5237.
Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34–42.
Newman MEJ. The structure and function of complex networks. SIAM Rev 2003;45:167–256.
Spoms O. Network analysis, complexity, and brain function. Complexity 2003;8:56–60.
Csete M, Doyle J. Bow ties, metabolism and disease. Trends Biotechnol 2004;22:446–450.
Achard S, Salvador R, Whitcher B, Suckling J, Bullmore E. A resilient, low-frequency, small-world human brain functional network with highly connected association cortical hubs. J Neurosci 2006;26:63–72.
Micheloyannis S, Pachou E, Stam CJ, Breakspear M, Bitsios P, Vourkas M. Small-world networks and disturbed functional connectivity in schizophrenia. Schizophr Res 2006;87:60–66.
Araujo RP, Liotta LA, Petricoin EF. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 2007;6:871–880.
He Y, Chen ZJ, Evans AC. Small-world anatomical networks in the human brain revealed by cortical thickness from MRI. Cereb Cortex 2007;17:2407–2419.
Ideker T, Sharan R. Protein networks in disease. Genome Res 2008;18:644–652.
May RM. Network structure and biology of populations. Trends Ecol Evol 2006;21:394–399.
Proulx SR, Promislow DEL, Phillips PC. Network thinking in ecology and evolution. Trends Ecol Evol 2005;20:345–353.
Schrattenholz A, Soskic V. What does systems biology mean for drug development? Curr Med Chem 2008;15: 1520–1528.
Fujisawa S, Matsuki N, Ikegaya Y. Single neurons can induce phase transitions of cortical recurrent networks with multiple internal states. Cereb Cortex 2006;16:639–654.
Kaiser M, Martin R, Andras P, Young MP. Simulation of robustness against lesions of cortical networks. Eur J Neurosci 2007;25:3185–3192.
Stam CJ, Jones BF, Nolte G, Breakspear M, Scheltens P. Small-world networks and functional connectivity in Alzheimer’s disease. Cereb Cortex 2007;17:92–99.
Szalay MS, Kovacs IA, Korcsmáros T, Böde C, Csermely P. Stress-induced rearrangements of cellular networks: consequences for protection and drug design. FEBS Lett 2007;581:3675–3680.
Lawson K. Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies? Drug Discov Today 2008;13:333–340.
Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20:29–42.
Van der Schyf CJ, Geldenhuys WJ, Youdim MBH. Multifunctional neuroprotective-neurorescue drugs for Parkinson’s disease. Future Neurol 2007;2:411–423.
Pinnen F, Cacciatore I, Comacchia C, et al. Synthesis and study of l-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties. J Med Chem 2007;50:2506–2515.
Bolognesi ML, Cavalli A, Valgimigli L, et al. Multi-target-directed drug design strategy: from a dual binding site acetylcho-linesterase inhibitor to a trifunctional compound against Alzheimer’s disease. J Med Chem 2007;50: 6446–6449.
Mandel S, Amit T, Bar-Am O, Youdim MBH. Iron dysregulation in Alzheimer’s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid processing regulatory activities as therapeutic agents. Prog Neurobiol 2007;82:348–360.
Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207–215.
Piazzi L, Cavalli A, Colizzi F, et al. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett 2008;18:423–426.
Araujo RP, Doran C, Liotta LA, Petricoin EF. Network-targeted combination therapy: a new concept in cancer treatment. Drug Discov Today Ther Strateg 2004;1:425–433.
Schenone S, Manetti F, Botta M. Last findings on dual inhibitors of Abl and Src tyrosine-kinases. Mini Rev Med Chem 2007;7:191–201.
Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422–432.
López-Muñoz F, Alamo C, Rubio G, García-García P, Pardo A. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2007;40:14–19.
Plenge P, Gether U, Rasmussen SG. Allosteric effects of R- and S-citalopram on human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. Eur J Pharmacol 2007;567:1–9.
Höschl C, Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother 2008;8:537–552.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Millan, M.J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 6, 53–77 (2009). https://doi.org/10.1016/j.nurt.2008.10.039
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2008.10.039